Blocking processes which keep leukaemia cells alive
Investigating the possibility of combining a medicine that blocks the process with a medicine that triggers a cell's defensive response to treat ALL.
Are regular blood and bone marrow tests helpful after childhood leukaemia?
Investigating the best follow up methods for childhood leukaemia to improve aftercare.
Precision medicines for paediatric acute myeloid leukaemia
Finding which MEK inhibitors work best for children with acute myeloid leukaemia.
A better way of delivering drugs for acute myeloid leukaemia
Testing nanoparticles as a way of getting drugs where they are needed for acute myeloid leukaemia.
Using existing drugs in a new way to treat high-risk acute lymphoblastic leukaemia
Finding drugs which target genes that drive high-risk acute lymphoblastic leukaemia.
Using genetics to understand why acute myeloid leukaemia cells don’t respond to treatment
Looking at the genetics of bone marrow samples to see which genes affect resistance to treatment.
Targeting proteins to fight acute myeloid leukaemia
Understanding how proteins act inside acute myeloid leukaemia cells, to find new drug targets.
Investigating how regulatory regions of the genome communicate with cancer causing genes
Finding which regulatory regions of the genome are causing leukaemia by acting on the wrong gene
Developing less toxic therapies for children with acute lymphoblastic leukaemia
Our proposal will deliver novel, less toxic targeted therapies with the potential to advance current treatment regimens for B-ALL. This will improve current outcomes, reduce side-effects in B-ALL patients and ultimately lead to a better quality of life for patients and their families.